This study is designed to determine the clinical efficacy and toxicity of ABT-869 in combination with carboplatin and paclitaxel in the treatment of subjects with advanced or metastatic NSCLC.

• Drug: ABT-869
  See arm for details
  Other Name: ABT-869
• Drug: Placebo
  see arm for details

• A: Experimental
  12.5 mg ABT-869
  Intervention: Drug: ABT-869
• B: Experimental
  7.5 mg ABT-869
  Intervention: Drug: ABT-869
• C: Placebo Comparator
  Placebo (7.5 mg or 12.5 mg)
  Intervention: Drug: Placebo

Inclusion Criteria:

• Subject must be at least 18 years of age.
• Subject must have cytologically or histologically confirmed non-squamous NSCLC
• Subject must have recurrent or advanced (Stage IIIb with pleural or pericardial effusion) or metastatic (Stage IV) disease that is not amenable to surgical resection or radiation with curative intent.
• Subject has measurable disease, defined as at least 1 unidimensional measurable lesion on a computed tomography (CT) scan as defined by RECIST (for subjects in the randomized portion only).
• Subject has an ECOG Performance Score of 0-1.
• Willing to take adequate measures to prevent pregnancy.

Exclusion Criteria:

• The subject has NSCLC with a predominant squamous cell histology
• Subject has hypersensitivity to paclitaxel.
• Subject has received any anti-cancer therapy for treatment of NSCLC.
• Subject has received radiation therapy within 21 days of Study Day 1.
• Subject has had major surgery within 21 days.
• Subject has untreated brain or meningeal metastases.
• Subject is receiving therapeutic anticoagulation therapy.
• Subject has a central thoracic tumor lesion as defined by location within the hilar structures.
• Subject has proteinuria CTC Grade > 1 at baseline.
• Subject has a history of, or currently exhibits clinically significant cancer related events of bleeding.
• The subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (BP) > 90 mm Hg or systolic BP > 140 mm Hg.
• The subject has a history of myocardial infarction, stroke or Transient Ischemic Attack (TIA) within 6 months of Study Day 1.
• The subject has a documented left ventricular (LV) ejection fraction < 50%.
• The subject has known autoimmune disease with renal involvement (i.e., lupus).
• The subject is receiving combination anti-retroviral therapy for HIV.
• The subject has clinically significant uncontrolled condition(s).
• The subject has a history of another active cancer within the past 5 years.
• The subject has active ulcerative colitis, Crohn's disease, celiac disease or any other conditions that interfere with absorption.
• The subject has a medical condition, which in the opinion of the study investigator places them at an unacceptably high risk for toxicities.
• The subject is pregnant or breast feeding.